1. Home
  2. AZUL vs CHRS Comparison

AZUL vs CHRS Comparison

Compare AZUL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AZUL
  • CHRS
  • Stock Information
  • Founded
  • AZUL 2008
  • CHRS 2010
  • Country
  • AZUL Brazil
  • CHRS United States
  • Employees
  • AZUL N/A
  • CHRS N/A
  • Industry
  • AZUL Air Freight/Delivery Services
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AZUL Consumer Discretionary
  • CHRS Health Care
  • Exchange
  • AZUL Nasdaq
  • CHRS Nasdaq
  • Market Cap
  • AZUL 207.6M
  • CHRS 191.3M
  • IPO Year
  • AZUL 2017
  • CHRS 2014
  • Fundamental
  • Price
  • AZUL $2.19
  • CHRS $1.32
  • Analyst Decision
  • AZUL Buy
  • CHRS Strong Buy
  • Analyst Count
  • AZUL 9
  • CHRS 4
  • Target Price
  • AZUL $6.23
  • CHRS $5.38
  • AVG Volume (30 Days)
  • AZUL 1.3M
  • CHRS 2.0M
  • Earning Date
  • AZUL 02-24-2025
  • CHRS 03-12-2025
  • Dividend Yield
  • AZUL N/A
  • CHRS N/A
  • EPS Growth
  • AZUL N/A
  • CHRS N/A
  • EPS
  • AZUL N/A
  • CHRS N/A
  • Revenue
  • AZUL $3,468,415,494.00
  • CHRS $304,340,000.00
  • Revenue This Year
  • AZUL N/A
  • CHRS $2.47
  • Revenue Next Year
  • AZUL $14.55
  • CHRS N/A
  • P/E Ratio
  • AZUL N/A
  • CHRS N/A
  • Revenue Growth
  • AZUL 4.33
  • CHRS 44.19
  • 52 Week Low
  • AZUL $1.57
  • CHRS $0.66
  • 52 Week High
  • AZUL $8.73
  • CHRS $2.87
  • Technical
  • Relative Strength Index (RSI)
  • AZUL 55.42
  • CHRS 41.91
  • Support Level
  • AZUL $1.95
  • CHRS $1.38
  • Resistance Level
  • AZUL $2.15
  • CHRS $1.60
  • Average True Range (ATR)
  • AZUL 0.12
  • CHRS 0.12
  • MACD
  • AZUL 0.08
  • CHRS -0.03
  • Stochastic Oscillator
  • AZUL 76.54
  • CHRS 1.10

About AZUL Azul S.A. (each representing three preferred shares)

Azul SA is involved in the operation of regular and non-regular airline passenger services, cargo or mail, passenger charter, provision of maintenance and hangarage services for aircraft, engines, parts and pieces, aircraft acquisition and lease, development of frequent-flyer programs, development of related activities and equity holding in other companies. The Company considers that it has a single reportable segment which is air transport.

About CHRS Coherus BioSciences Inc.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Share on Social Networks: